Finance

Lists
Why is 600664 down 6.10%?
Dive Deeper
600664:SHA
Harbin Pharmaceutical Group Co Ltd
CN¥6.16
-6.10%
(-0.40) 1D
Oct 14, 3:00:02 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600664...
Open
CN¥6.35
High
CN¥6.50
Low
CN¥6.13
Mkt. cap
16.52B
Avg. vol.
392.52M
Volume
331.69M
P/E ratio
30.29
52-wk high
CN¥9.86
52-wk low
CN¥2.84
EPS
CN¥0.20
Shares outstanding
2.54B
No. of employees
10K
Open
CN¥6.35
High
CN¥6.50
Low
CN¥6.13
Mkt. cap
16.52B
Avg. vol.
392.52M
Volume
331.69M
P/E ratio
30.29
52-wk high
CN¥9.86
52-wk low
CN¥2.84
EPS
CN¥0.20
Shares outstanding
2.54B
No. of employees
10K
News stories
From web sources and news partners
Profile
Harbin Pharmaceutical Group Co., Ltd. is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. HPGC medication offerings include traditional Chinese medicine and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate. The company owns both Renmintongtai, a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products. Wikipedia
About Harbin Pharmaceutical Group Co Ltd
CEO-
Employees10K
Founded1988
Headquarters-
SectorPharmaceutical industry
Websitehayao.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.90B
3.94B
4.18B
4.12B
Cost of goods sold
2.95B
2.96B
3.17B
2.96B
Cost of revenue
2.95B
2.96B
3.17B
2.96B
Research and development expenses
33.63M
51.31M
27.02M
33.38M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
753.48M
815.96M
721.16M
803.44M
Operating expense
838.57M
897.00M
786.62M
895.87M
Total operating expenses
3.78B
3.85B
3.96B
3.86B
Operating income
112.30M
88.76M
219.91M
264.89M
Other non operating income
468.22K
-13.01M
-7.97M
1.21M
EBT including unusual items
119.12M
91.70M
206.43M
311.43M
EBT excluding unusual items
109.94M
63.73M
208.13M
254.28M
Income tax expense
41.30M
34.62M
45.36M
63.42M
Effective tax rate
34.67%
37.75%
21.97%
20.37%
Other operating expenses
24.67M
29.19M
21.94M
53.95M
Net income
68.89M
33.00M
161.13M
249.19M
Net profit margin
1.77%
0.84%
3.86%
6.05%
Earnings per share
-
-
-
-
Interest and investment income
4.05M
3.14M
4.20M
6.12M
Interest expense
-11.05M
-10.76M
-8.01M
-10.10M
Net interest expenses
-7.00M
-7.62M
-3.81M
-3.98M
Depreciation and amortization charges
-
-
-
-
EBITDA
166.37M
143.03M
274.17M
320.66M
Gain or loss from assets sale
3.99M
-3.83M
-
-35.83M
AI content may include mistakes. Learn more
Google apps